Evidence map›Paper›PMID 40729427›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Associations of Nucleoside Diphosphate-Linked Moiety X-Type Motif 15 Variants With Neutropenia During Antiviral Therapy for Cytomegalovirus Disease in Pediatric Liver Transplant Recipients.

Ken-Ichi Iwata, Yuka Torii, Yuto Fukuda, Kazunori Haruta, Makoto Yamaguchi, Takako Suzuki, Yasuhiro Ogura, Jun-Ichi Kawada

Abstract read
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ken-Ichi IwataDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuka ToriiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuto FukudaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazunori HarutaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Makoto YamaguchiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takako SuzukiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiro OguraDepartment of Transplantation Surgery, Nagoya University Hospital, Nagoya, Japan.
Jun-Ichi KawadaDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.

Funding

Japan Agency for Medical Research and DevelopmentJapanese Research Foundation for Clinical PharmacologyJapan Society for the Promotion of Science 2023A18
6 · The paper itself

Abstract

backgroundCytomegalovirus (CMV) infection in pediatric liver transplant recipients is a major concern. Ganciclovir (GCV) and valganciclovir (VGCV) are the first-line treatment agents; however, neutropenia is a common adverse effect. Nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) variants are linked to thiopurine-induced myelosuppression; however, their associations with GCV/VGCV-induced cytotoxicity remain unclear. We aimed to examine the association between loss-of-function variants of the NUDT15 genotype and drug-related adverse reactions in pediatric transplant recipients, specifically liver transplant recipients, treated with GCV/VGCV.

methodsWe retrospectively analyzed data from pediatric liver transplant recipients treated with GCV/VGCV for CMV disease or infection between 2012 and 2022. Patients were genotyped for NUDT15 R139C, R139H, and V18I variants, and hematological outcomes were compared between the normal and variant groups.

resultsOf 40 patients, 10 (25%) harbored NUDT15 variants. The incidence rate of neutropenia (60% vs. 7%; p < 0.01) and percentage decrease in neutrophil count (-65.1% vs. -45.9%; p = 0.02) were significantly higher in the variant group than in the normal group. No significant differences were observed in the incidence of leukopenia, anemia, thrombocytopenia, hepatic toxicity, or renal toxicity.

conclusionNUDT15 variants were associated with an increased risk of neutropenia in pediatric liver transplant recipients receiving GCV/VGCV treatment. Genetic screening before treatment initiation may help optimize antiviral therapy, minimize hematological toxicity, and improve patient management. Further studies are needed to refine the treatment strategies.

Indexed as

Antiviral AgentsCytomegalovirus InfectionsLiver TransplantationNeutropeniaPyrophosphatasesAdolescentChildChild, PreschoolCytomegalovirusFemaleGanciclovirGenotypeHumansInfantMaleNudix HydrolasesAntiviral AgentsGanciclovirNudix HydrolasesNUDT15 protein, humanPyrophosphatasesValganciclovir

Identifiers

PMID40729427
PMCPMC12519940

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.